Syndax Pharmaceuticals: Oversold Pharma Likely To Benefit From Drug Approvals

• click to rate

  Posted by Two Blokes Jul 8 - Filed in Stock - 5 views
  
  Syndax now has two approved therapies—NIKTIMVO and Revuforj—but the share price remains under pressure despite these milestones. NIKTIMVO faces a crowded cGVHD market and skepticism about its commercial potential, with analysts projecting modest long-term sales. Revuforj offers significant upside, targeting an underserved leukemia niche with minimal competition and potential for label expansion pending FDA review.